Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 9/20 | 0.32 |
| ▸ | BCL2 | P10415 | 5/20 | 0.32 |
| ▸ | BCL2L1 | Q07817 | 4/20 | 0.32 |
| ▸ | KRAS | P01116 | 2/20 | 0.32 |
| ▸ | MET | P08581 | 1/20 | 0.32 |
| ▸ | CYP8B1 | Q9UNU6 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21050877 | 0.89 | KRAS (0.33) | KRASCYP8B1 | |
| SCHEMBL21050733 | 0.89 | KRAS (0.33) | KRASCYP8B1 | |
| SCHEMBL21137316 | 0.87 | MET (0.39) | GPR119METCYP8B1ALDH1A1 | |
| SCHEMBL21099203 | 0.87 | MET (0.39) | GPR119METCYP8B1ALDH1A1 | |
| SCHEMBL21099361 | 0.87 | MET (0.39) | GPR119METCYP8B1ALDH1A1 | |
| SCHEMBL21099385 | 0.86 | GPR119 (0.36) | GPR119MCL1BCL2BCL2L1KRAS | |
| SCHEMBL21099334 | 0.86 | GPR119 (0.36) | GPR119MCL1BCL2BCL2L1KRAS | |
| SCHEMBL21137056 | 0.85 | GPR119 (0.41) | GPR119METCYP8B1MEN1KMT2A | |
| SCHEMBL21050760 | 0.81 | CYP8B1 (0.31) | KRASCYP8B1 | |
| SCHEMBL21099607 | 0.81 | MET (0.39) | GPR119METCYP8B1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190177338-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2019-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177338-A1 | CHEMICAL COMPOUNDS | MKI67, CCNI, MCL1 | GPR119 945/4885MCL1 3/4885BCL2 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.